Financial Release TSPC SM1 2026.pdf

The principal contributors to Tempo Scan's First Half 2026 net sales
performance were as follows:

1)

2)

3)

Tempo Scan's CPC division delivered the strongest net sales growth, with
net sales increased by 10.6Yo to Rp.2,478.7 billion. The division's Consumer
Products group recorded net sales growth of 10.196 to Rp.1,957.2 billion, while its
Cosmetics group achieved egually a commendable net sales growth of 12.76 to
Rp.521.5 billion. The Consumer Products and Cosmetics groups contributed 79.0Yo and
21.0Yo, respectively, to the CPC division's net sales.

From a geographical perspective, the CPC division's domestic net sales grew by 10.8Ys
to Rp.2,359.4 billion, while its International Business net sales increased by 6.8Y6 to
Rp.119.3 billion. Conseguently, the CPC division's contribution to Tempo Scan's
consolidated net sales increased to 34.9Yo, compared with 34.0Y6 in First Half 2025.

Tempo Scan's Pharma division achieved net sales growth of 8.6Yo to
Rp.2,414.8 billion. The division's Consumer Health products, including Nutrition,
increased by 8.8Y6 to Rp.2,374.3 billion. Within this group, Consumer Health products
excluding Nutrition rose by 10.796 to Rp.1,230.2 billion, while Nutrition products grew
by 6.8Y6 to Rp.1,144.1 billion. The Prescription Medicines group's net sales remained
broadly stable at Rp.40.5 billion.

The Pharma division's domestic net sales grew strongly by 10.9Yo to Rp.2,310.3 billion.
The division's International Business net sales amounted to Rp.104.5 billion.
Accordingly, the Pharma division contributed 34.0Yo to Tempo Scan's consolidated net
sales, compared with 33.796 in First Half 2025.

Tempo Scan's Distribution division recorded net sales growth of 3.8 to
Rp.2,216.4 billion. Net sales of external pharmaceutical principals' products rose by
19.7Y6 to Rp.298.7 billion, while external non-pharmaceutical principals' products
increased by 1.796 to Rp.1,917.7 billion. The Distribution division contributed 31.2Yo to
Tempo Scan's consolidated net sales.

First Half 2026 Gross Profit and Gross Profit Margin

Tempo Scan's gross profit increased by 8.7Yo to Rp.2,654.2 billion, exceeding
its net sales growth of 7.740. Conseguentiy, its consolidated gross profit margin
has improved to 37.3Yo, from 37.0Y6 in First Half 2025. This result was achieved
despite higher costs for certain imported raw materials amongst other due to Rupiah
weakening, oil-linked packaging materials price increase, higher fuel and freight cost
following the escalation of conflict in the Middle East. The Company mitigated these

pressures through service level continuous improvement, Strategic procurement
implementation, increasing manufacturing productivity, product-mix management and IT
development including AI application.

Gross profit from Tempo Scan's Pharma division increased by 7.5Y6 to Rp.1,173.3 billion,
the CPC division increased by 11.1Yo to Rp.1,296.1 billion, while the Distribution division
increased by 0.9Yo to Rp.184.8 billion.

First Half 2026 Operating Expenses and Profitability

Tempo Scan continued to exercise cost management discipline including over advertising
and promotion activities and other operating expenditure, prioritising initiatives that
supported its brand eguities development, consumer conversion and sustainable sales
growth. Its total selling expenses amounted to Rp.1,540.9 billion, an increase of 15.9Yo,
reflecting continued commercial and brand-support activities. General and administrative
expenses were effectively controlled, increasing by 4.7Y6 to Rp.369.3 billion. Conseguently,
the ratio of such general and administrative expenses to net sales has declined to 5.2Y4,
from 5.396 in First Half 2025.

In addition, its net other operating income increased to Rp.141.6 billion, compared with
Rp.50.5 billion in the corresponding period last year. As a result, Tempo Scan's operating
profit grew by 9.4” to Rp.885.6 billion, while its operating profit margin
improved to 12.5Yo, from 12.3Yo in First Half 2025.

Tempo Scan's profit before tax increased by 7.3Yo to Rp.941.3 billion. More
importantly, its net profit after tax attributable to eguity holders of the parent
company grew by 10.36 to Rp.774.8 billion, with the corresponding net profit
margin improving to 10.9”, compared to 10.6Yo in First Half 2025. Earnings per
share increased by 10.3Yo to Rp.172 in First Half 2026, from Rp.156 in the prior year period.

Tempo Scan's EBITDA increased by 9.8Y6 to Rp.1,064.7 billion, while its EBITDA
margin improved to 15.096, from 14.7Yo in the corresponding period last year. These
results reflected the Company's ability to translate healthy sales growth and a resilient
gross profit margin into sustainable earnings growth.
Balance Sheet and Liguidity as of 30 June 2026

Tempo Scan maintained a very solid balance sheet as of 30 June 2026. Cash and
cash eguivalents increased by 22.46 to Rp.5,367.0 billion, compared with Rp.4,385.4
billion as of 30 June 2025. Total assets increased by 11.3Yo to Rp.14,198.4 billion, while
shareholders' eguity rose by 8.2Y6 to Rp.10,217.1 billion. |

While its current ratio remained healthy at approximately 2.9 times, and net operating
cycle has improved considerably to 74 days compared to 88 days in First Half
2025. This strong liguidity position provides Tempo Scan with substantial financial
flexibility to overcome challenges, support its working capital reguirements, capital
expenditures and strategic growth initiatives.

Closing Message

Amid continued global and domestic economic, geopolitical and policy uncertainties, Tempo
Scan remains resolute in upholding its commitment to "Work WholeheartedIy for Indonesia"
while advancing its strategic objectives. Tempo Scan will continue to strengthen its brand
eguities, expand its distribution coverage especially outside Java, increase its
manufacturing capacities and productivity, enhance new products pipeline with Innovation
and maintain prudent financial management, in order to deliver high-guality and
competitively priced products and services to its consumers.

Tempo Scan's Board of Directors would like to express its highest appreciation to its
Executive Chairman & President Commissioner for pursuing the company strategies and
executions, its management leadership and all employees for their dedication, commitment
and relentless hard work. The Board of Directors also extends its sincere gratitude to
shareholders, business partners, suppliers, healthcare professionals, customers and all
stakeholders whose continued trust and support have enabled Tempo Scan to achieve the
above financial results.

Jakarta, 30 July 2026
On behalf of PT Tempo Scan Pacific Tbk

Liza Prasodjo
Vice President Director

Copies:
- Mr. Handojo S. Muljadi, Tempo Scan's President Commissioner
- Tempo Scan's Board of Directors